^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
…larotrectinib or enterectinib if NTRK gene fusion positive…
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Solid Tumor)
New
Excerpt:
ROZLYTREK is a kinase inhibitor indicated for the treatment of...Adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation.